Profile data is unavailable for this security.
About the company
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
- Revenue in EUR (TTM)1.76bn
- Net income in EUR357.94m
- Incorporated1996
- Employees5.65k
- LocationQiagen NVHulsterweg 82VENLO 5912 PLNetherlandsNLD
- Phone+31 773556600
- Fax+31 773208409
- Websitehttps://www.qiagen.com/
More ▼
Mergers & acquisitions
| Acquired company | QIAX:GER since announced | Transaction value |
|---|---|---|
| Parse Biosciences Inc | 8.40% | 280.00m |
| GNX Data Systems Inc | 13.90% | 80.00m |
Data delayed at least 15 minutes, as of Feb 12 2026 16:35 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vaxcyte Inc | 0.00 | -657.20m | 7.81bn | 414.00 | -- | 2.49 | -- | -- | -4.84 | -4.84 | 0.00 | 22.25 | 0.00 | -- | -- | 0.00 | -19.53 | -26.00 | -20.51 | -27.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.33 | -- | 151.05 | -- |
| Nuvalent Inc | 0.00 | -381.44m | 7.97bn | 218.00 | -- | 8.82 | -- | -- | -5.32 | -5.32 | 0.00 | 11.70 | 0.00 | -- | -- | 0.00 | -35.18 | -25.32 | -37.61 | -26.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -106.59 | -- | -- | -- |
| Cytokinetics, Inc. | 87.21m | -751.94m | 8.17bn | 498.00 | -- | -- | -- | 93.65 | -6.31 | -6.31 | 0.7328 | -4.27 | 0.0607 | -- | 85.00 | 175,122.50 | -52.35 | -45.50 | -57.39 | -50.38 | -- | -- | -862.21 | -748.37 | -- | -14.45 | 1.96 | -- | 145.34 | -7.22 | -12.03 | -- | 8.32 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.02bn | -83.48m | 8.17bn | 18.60k | -- | 2.40 | 23.51 | 2.03 | -1.56 | -1.56 | 80.18 | 69.20 | 0.5186 | 8.23 | 5.41 | 216,328.20 | -1.03 | 5.12 | -1.20 | 6.01 | 34.68 | 36.56 | -1.98 | 9.47 | 1.10 | 3.18 | 0.388 | 0.00 | -1.92 | 9.09 | -97.83 | -47.25 | 10.64 | -- |
| Arrowhead Pharmaceuticals Inc | 1.09bn | 202.27m | 8.62bn | 711.00 | 39.94 | 14.88 | 33.32 | 7.90 | 1.54 | 1.54 | 7.90 | 4.14 | 0.8335 | -- | 9.86 | 1,534,432.00 | 17.84 | -25.96 | 21.44 | -30.82 | -- | -- | 21.41 | -76.01 | -- | 5.91 | 0.5068 | -- | 23,258.15 | 56.63 | 99.73 | -- | 13.66 | -- |
| Praxis Precision Medicines Inc | 7.46m | -273.04m | 8.86bn | 116.00 | -- | 19.92 | -- | 1,187.25 | -12.90 | -12.90 | 0.3533 | 16.23 | 0.0184 | -- | -- | 64,336.21 | -67.20 | -70.37 | -75.12 | -79.85 | -- | -- | -3,658.53 | -6,809.15 | -- | -- | 0.00 | -- | 249.53 | -- | -48.30 | -- | -- | -- |
| Tempus AI Inc | 1.11bn | -203.88m | 9.54bn | 2.40k | -- | 18.77 | -- | 8.63 | -1.18 | -1.18 | 6.45 | 2.86 | 0.6795 | 9.29 | 5.15 | 460,524.20 | -12.53 | -53.69 | -15.38 | -72.10 | 61.73 | 45.68 | -18.45 | -84.29 | 3.12 | -3.83 | 0.7104 | -- | 30.38 | 62.05 | -180.61 | -- | 5.36 | -- |
| BIO-TECHNE Corp | 1.22bn | 79.96m | 9.93bn | 3.10k | 125.01 | 4.92 | 54.03 | 8.17 | 0.5076 | 0.5076 | 7.74 | 12.90 | 0.4682 | 2.06 | 6.04 | 392,121.60 | 3.08 | 7.62 | 3.27 | 8.13 | 66.60 | 67.49 | 6.58 | 16.74 | 3.08 | 56.92 | 0.1145 | 26.72 | 5.23 | 10.55 | -56.35 | -20.37 | -9.74 | -4.36 |
| ICON PLC | 8.10bn | 599.48m | 10.17bn | 39.80k | 18.00 | 1.09 | 10.29 | 1.25 | 7.40 | 7.40 | 101.04 | 122.25 | 0.4806 | -- | 3.00 | 193,379.50 | 3.56 | 3.70 | 4.33 | 4.46 | 28.15 | 29.00 | 7.40 | 7.41 | -- | 5.94 | 0.2675 | -- | 1.99 | 24.17 | 29.26 | 16.18 | 27.11 | -- |
| Qiagen NV | 2.09bn | 424.88m | 10.51bn | 5.65k | 25.58 | 2.93 | 17.00 | 5.03 | 2.00 | 2.00 | 9.80 | 17.45 | 0.3488 | 2.66 | 5.45 | 369,649.60 | 7.09 | 5.89 | 7.77 | 6.96 | 62.97 | 63.60 | 20.33 | 17.13 | 3.31 | -- | 0.3045 | -- | 5.65 | 2.25 | 408.28 | 3.42 | -7.40 | -- |
| Madrigal Pharmaceuticals Inc | 740.64m | -289.13m | 10.92bn | 528.00 | -- | 17.45 | -- | 14.75 | -13.01 | -13.01 | 33.39 | 27.56 | 0.6082 | 0.9008 | 10.30 | 1,402,727.00 | -23.74 | -68.48 | -30.98 | -85.32 | 95.25 | -- | -39.04 | -876.55 | 3.26 | -- | 0.3519 | -- | -- | -- | -24.69 | -- | 106.52 | -- |
| Exelixis Inc | 2.32bn | 782.57m | 11.15bn | 1.08k | 15.43 | 5.21 | 13.74 | 4.81 | 2.78 | 2.78 | 8.23 | 8.23 | 0.8011 | 3.80 | 8.40 | 2,154,249.00 | 27.02 | 13.68 | 31.41 | 15.65 | 96.39 | 96.33 | 33.73 | 20.55 | 3.50 | -- | 0.00 | 0.00 | 6.98 | 18.63 | 50.13 | 47.58 | -22.60 | -- |
| Summit Therapeutics Inc | 0.00 | -921.62m | 11.35bn | 159.00 | -- | 59.05 | -- | -- | -1.24 | -1.24 | 0.00 | 0.2583 | 0.00 | -- | -- | 0.00 | -241.08 | -78.31 | -287.72 | -86.84 | -- | -- | -- | -31,307.77 | -- | -- | 0.00 | -- | -- | -- | 64.01 | -- | -16.43 | -- |
| Medpace Holdings Inc | 2.53bn | 451.12m | 12.03bn | 5.90k | 27.73 | 26.13 | 25.11 | 4.76 | 15.29 | 15.29 | 85.67 | 16.22 | 1.24 | -- | 7.24 | 428,853.20 | 22.13 | 18.52 | 55.42 | 37.53 | 30.06 | 29.60 | 17.83 | 17.15 | -- | -- | 0.00 | 0.00 | 19.97 | 22.27 | 11.57 | 25.50 | 0.0102 | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -3.58m | 13.21bn | 12.00 | -- | 2,718.52 | -- | -- | -0.0073 | -0.0073 | 0.00 | 0.0098 | 0.00 | -- | -- | 0.00 | -50.50 | -53.93 | -53.75 | -65.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 16.68 | -- | 5.32 | -- |
| Ionis Pharmaceuticals Inc | 966.96m | -256.34m | 13.66bn | 1.07k | -- | 21.99 | -- | 14.13 | -1.71 | -1.71 | 5.87 | 3.84 | 0.3163 | 0.6054 | 45.47 | 904,542.60 | -8.39 | -11.71 | -10.45 | -13.72 | 98.78 | 98.42 | -26.51 | -44.15 | 2.78 | -- | 0.7414 | -- | -10.48 | -8.88 | -23.92 | -- | 7.94 | -- |
Data as of Feb 12 2026. Currency figures normalised to Qiagen NV's reporting currency: US Dollar USD
0.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Massachusetts Financial Services Co.as of 09 Jan 2026 | 11.52m | 0.00% |
| BlackRock Fund Advisorsas of 30 Jan 2026 | 8.97m | 0.00% |
| BlackRock Advisors (UK) Ltd.as of 30 Jan 2026 | 3.67m | 0.00% |
| DWS Investment GmbHas of 03 Feb 2026 | 3.21m | 0.00% |
| BlackRock Asset Management Deutschland AGas of 30 Jan 2026 | 2.33m | 0.00% |
| BlackRock Investment Management (UK) Ltd.as of 30 Jan 2026 | 1.24m | 0.00% |
| BlackRock Advisors LLCas of 30 Jan 2026 | 452.04k | 0.00% |
| State Street Global Advisors Ltd.as of 08 Jan 2026 | 129.38k | 0.00% |
| Palatine Asset Management SAas of 30 Jan 2026 | 74.56k | 0.00% |
| DWS Investment SAas of 08 Jan 2026 | 45.57k | 0.00% |
More ▼
Data from 30 Sep 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
